May 23rd 2023
Plans have been made to file a new drug application in China for roxadustat as a treatment for chemotherapy-induced anemia in those with non-myeloid malignancies.
Tumor Board: How The Experts Approach Personalized Care Plans in ER-Positive Breast Cancer
View More
Tumor Board: How The Experts Approach Personalized Care Plans in ER-Positive Breast Cancer
View More
Community Practice Connections™: Translating Recent Evidence on CAR T-Cell Therapy to the Real-World Management of Lymphoid Malignancies
View More
7th Annual International Congress on Oncology & Pathology™: Towards Harmonization of Pathology and Oncology Standards
View More
Community Practice Connections™: Evolving Paradigms in Transplant-Related CMV Prevention and Management: Setting Foundations for Improved Patient Outcomes
View More
Evolving Paradigms in Transplant-Related CMV Prevention and Management: Setting Foundations for Improved Patient Outcomes
View More
CAR T-Cell Therapy in Multiple Myeloma: Key Considerations for Patient Selection, Transplant, and Applying Recent Data
View More
Optimizing ASCT in Patients With Multiple Myeloma and Non-Hodgkin Lymphoma Through Stem Cell Mobilization Techniques
View More
Expert Illustrations & Commentaries™: The Role of B7-H3 Across Tumor Types and How It Could Impact Your Practice in the Future
View More
Expert Illustrations & Commentaries™: The Role of B7-H3 Across Tumor Types and How It Could Impact Your Practice in the Future
View More
Expert Illustrations & Commentaries™: The Role of B7-H3 Across Tumor Types and How It Could Impact Your Practice in the Future
View More
Expert Illustrations & Commentaries™: The Role of B7-H3 Across Tumor Types and How It Could Impact Your Practice in the Future
View More
Medical Crossfire®: Experts Address Burning Questions in DLBCL—Sequencing CD19-Targeted Therapies, Strategies Post-CAR T Relapse, Novel Agents, and More!
View More
Improving Outcomes in Autoimmune Hemolytic Anemias at the Intersection Between Hematology and Oncology Care
View More
B-Cell Tumor Board: Rendering Real World Personalized Treatment Plans in CLL/SLL and MCL Through the Lens of Emerging BTKi Evidence
View More
Medical Crossfire®: Everything You Need to Know About the PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Medical Crossfire®: Everything You Need to Know About the PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Medical Crossfire®: Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!
View More
Medical Crossfire®: Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!
View More
Live “Hot Seat”: Experts Face Your Hot-Button Questions on Maximizing PARP Inhibitors in Patients with CRPC
View More
Live “Hot Seat”: Experts Face Your Hot-Button Questions on Maximizing PARP Inhibitors in Patients with CRPC
View More
Expanding the Armamentarium of Actionable Mutations in NSCLC: Uncovering the Potential of CEACAM5 as a Therapeutic Target
View More
Expanding the Armamentarium of Actionable Mutations in NSCLC: Uncovering the Potential of CEACAM5 as a Therapeutic Target
View More
Staying Abreast of the Prostate Cancer Treatment Paradigm From Risk Stratification to Adaptive Sequencing Strategies
View More
Staying Abreast of the Prostate Cancer Treatment Paradigm From Risk Stratification to Adaptive Sequencing Strategies
View More
Medical Crossfire®: Everything You Need to Know About the PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Medical Crossfire®: Everything You Need to Know About the PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
On-Demand Video Updates from the Annual Oncology Meeting
View More
On-Demand Video Updates from the Annual Oncology Meeting
View More
Medical Crossfire®: Leveraging Multidisciplinary Teams in Early Stage Breast Cancer When the Goal is Cure
View More
Abatacept Combo May Reduce Immunotherapy-Related Myotoxicity in Cancer
March 8th 2023Abatacept plus ruxolitinib and screenings for concomitant respiratory muscle failure may be effective in reducing the rate of mortality related to immune checkpoint inhibitor–associated myocarditis among patients with cancer.
FDA Approves Pegfilgrastim Biosimilar to Mitigate Febrile Neutropenia From Chemo
March 6th 2023A prefilled autoinjector presentation of pegfilgrastim-cbqv, a pegfilgrastim biosimilar, has been approved by the FDA for patients with cancer undergoing chemotherapy who may experience febrile neutropenia.
NCCN Guidelines Update Includes Injection for Cisplatin Ototoxicity in AYAs
February 14th 2023A medical oncologist and research audiologist from St. Jude Children’s Research Hospital discuss how sodium thiosulfate injection may improve quality of life by preventing cisplatin-associated ototoxicities in pediatric patients with localized non-metastatic tumors, although more research is needed.
Trilaciclib Prior to Sacituzumab Govitecan-hziy Appeared to Reduce AEs in Advanced TNBC
November 3rd 2022Initial findings from a phase 2 trial showed trilaciclib given before sacituzumab govitecan-hziy lessened the severity of adverse effects in patients with unresectable locally advanced or metastatic triple-negative breast cancer.
EC-18 Yields Positive Results for Chemoradiation-Induced Oral Mucositis in Head and Neck Cancer
October 21st 2021A phase 2 trial examining the use of small molecule immunomodulator EC-18 in patients with head and neck cancer experiencing chemoradiation-induced oral mucositis met its primary and secondary end points.